☆ 4.5 Article

Cost-effectiveness analysis of interventional liver-directed therapies for downstaging of HCC before liver transplant

LIVER TRANSPLANTATION (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Gastroenterology & Hepatology

UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies

Darren Jun Hao Tan et al.

Summary: This study assessed the success rates of down-staging treatment in HCC patients and evaluated outcomes based on different criteria for baseline tumor burden. The results showed that among patients who adhered to the UNOS-DS criteria, down-staging was successful in 83.21% of cases, over half of the patients received liver transplantation, and post-transplantation outcomes were excellent. These findings provide clinical validation for the utilization of UNOS-DS criteria.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States

Allison J. Kwong et al.

Summary: The utilization of locoregional therapy, especially radioembolization, is increasing among liver transplant candidates in the United States. Patients with greater tumor burden and more compensated liver disease receive more treatments while waiting for transplantation. Bridging therapy is associated with a lower risk of waitlist dropout.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Maria Reig et al.

Summary: There have been significant advances in the treatment strategies for hepatocellular carcinoma since the last update in 2018. However, some interventions still lack sufficient data for clinical incorporation, and personalized clinical management requires consideration of multiple parameters.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial

Elisabeth Dhondt et al.

Summary: This study compared the efficacy and safety of Y-90 glass TARE and DEB-TACE for unresectable HCC. The results showed that TARE conferred superior tumor control and overall survival compared to DEB-TACE. Both treatments had similar safety profiles.

RADIOLOGY (2022)

添加到收藏夹

Article Oncology

The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization

Derek Manas et al.

Summary: The study suggests that TheraSphere treatment may be a potentially cost-effective option for patients with early to intermediate stage HCC, with TheraSphere patients predicted to gain more QALYs compared to other treatments. The base case ICERs for TheraSphere were 17,300 pound, 17,279 pound and 23,020 pound per QALY gained compared to TAE, cTACE and DEB-TACE, respectively.

EJSO (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial

Etienne Garin et al.

Summary: This study compared the efficacy of personalized versus standard dosimetry in selective internal radiation therapy for advanced hepatocellular carcinoma, showing that personalized dosimetry significantly improved the objective response rate. The results suggest that personalized dosimetry may enhance outcomes in clinical practice and should be considered for future trials.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study

Riad Salem et al.

Summary: The LEGACY study evaluated the efficacy of yttrium-90 glass microspheres in treating solitary, unresectable HCC <= 8 cm, showing promising response rates and durable responses in a multicenter setting.

HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium

Neil Mehta et al.

Summary: This study is the first multiregional study based on UNOS-DS criteria, showing a successful downstaging rate of >80% and similar efficacy of chemoembolization and yttrium-90 radioembolization as the initial downstaging treatment. Despite a 2-year post-LT survival rate of 95%, a high rate of tumor understaging was observed.

GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria

Helena Degroote et al.

Summary: Successful downstaging of more advanced hepatocellular carcinoma (HCC) within the UCSF-DS protocol to the conventional Milan criteria does not result in a higher recurrence rate after liver transplantation (LT) compared to patients remaining within Milan criteria. Additionally, in the UCSF-DS group, an ALP value equal to or below 20 ng/ml at listing might be a novel tool to further optimize selection of candidates for LT.

JHEP REPORTS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time

Neil Mehta et al.

HEPATOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Validation of the Liver Disease Quality of Life Instrument 1.0 in Patients with Chronic Hepatitis B: A Prospective Study

Yeonjung Ha et al.

JOURNAL OF CLINICAL MEDICINE (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

AASLD guidelines for the treatment of hepatocellular carcinoma

Julie K. Heimbach et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study

Neil Mehta et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience

Riad Salem et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Peter R. Galle et al.

JOURNAL OF HEPATOLOGY (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Radiation Segmentectomy versus Selective Chemoembolization in the Treatment of Early-Stage Hepatocellular Carcinoma

Derek M. Biederman et al.

JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization

Ahmed Gabr et al.

EUROPEAN JOURNAL OF RADIOLOGY (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma

Riad Salem et al.

GASTROENTEROLOGY (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Downstaging of hepatocellular cancer before liver transplant: Long-term outcome compared to tumors within Milan criteria

Francis Y. Yao et al.

HEPATOLOGY (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

Cost-Effectiveness Analysis of Liver Resection Versus Transplantation for Early Hepatocellular Carcinoma Within the Milan Criteria

Kheng Choon Lim et al.

HEPATOLOGY (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

Emerging Trends in Hepatocellular Carcinoma Incidence and Mortality

Basile Njei et al.

HEPATOLOGY (2015)

添加到收藏夹

Article Oncology

Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma

R. Golfieri et al.

BRITISH JOURNAL OF CANCER (2014)

添加到收藏夹

Review Transplantation

Hepatocellular cancer: how to expand safely inclusion criteria for liver transplantation

Quirino Lai et al.

CURRENT OPINION IN ORGAN TRANSPLANTATION (2014)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Cost Effectiveness of Radioembolization Compared with Conventional Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma

Nassir Rostambeigi et al.

JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2014)

添加到收藏夹

Article Surgery

A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus Radioembolization

R. J. Lewandowski et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2009)

添加到收藏夹

Article Surgery

Liver Transplantation for Hepatocellular Carcinoma: Results of Down-Staging in Patients Initially Outside the Milan Selection Criteria

M. Ravaioli et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2008)

添加到收藏夹

Article Surgery

Outcomes of Neoadjuvant Transarterial Chemoembolization to Downstage Hepatocellular Carcinoma Before Liver Transplantation

William C. Chapman et al.

ANNALS OF SURGERY (2008)

添加到收藏夹

Article Gastroenterology & Hepatology

Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma

Gerd Otto et al.

LIVER TRANSPLANTATION (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.